Drug-eluting stents (DES) have become more widely used by cardiologists than bare metal
stents (BMS) because of their better ability to control restenosis. However, recognized …

The first percutaneous coronary intervention (PCI) was performed in September 1977 by
Andreas Grüntzig using a rudimentary balloon angioplasty catheter mounted on a fixed wire …

Background Despite rapid dissemination of an everolimus-eluting bioresorbable scaffold for
treatment for coronary artery disease, no data from comparisons with its metallic stent …

The drug release profile of drug-eluting stents (DESs) is affected by a number of factors,
including the formulation, design, and physicochemical properties of the utilized material …

Percutaneous coronary interventions (PCI) were proposed in the late 1970s as an
alternative to surgical coronary artery bypass grafting for the treatment of coronary artery …

Background and Methods It is important to ensure that blood flow is modelled accurately in
numerical studies of arteries featuring drug-eluting stents due to the significant proportion of …

Although drug-eluting stents (DES) are now widely used for the treatment of coronary heart
disease, there remains considerable scope for the development of enhanced designs which …

Drug-eluting stents are accepted as mainstream endovascular therapy, yet concerns for their
safety may be under-appreciated. While failure from restenosis has dropped to below 5 …

Stents have become the most successful device to treat advanced atherosclerotic lesions.
However, one of the main issues with these interventions is the development of restenosis …

Traditional coronary drug-eluting stents (DES) are made from metal and are coated with a
permanent polymer film containing an anti-proliferative drug. Subsequent to stent …